Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InBody CoXKRX:041830 -3.60%86 Days Payable is 27.32 as of Jun. 2026, which is 461% above its 10-year median of 4.87. GuruFocus rates XKRX:041830 with a GF Score™ of 86/100 and a GF Value™ of ₩35,473.99 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 796 Medical Devices & Instruments companies, InBody Co ranks worse than 95.23% on this metric.
InBody Co's average Accounts Payable for the
three
months ended in Jun. 2026 was ₩4,295 Mil. InBody Co's Cost of Goods Sold for the
three
months ended in Jun. 2026 was ₩14,342 Mil.
Hence, InBody Co's Days Payable for the
three
months ended in Jun. 2026 was 27.32.
The historical rank and industry rank for InBody Co's Days Payable or its related term are showing as below:
XKRX:041830'
s Days Payable Range Over the Past 10 Years
Min: 0.88 Med: 4.87 Max: 16.98
Current: 16.98
During the past 13 years, InBody Co's highest Days Payable was 16.98. The lowest was 0.88. And the median was 4.87.
XKRX:041830's Days Payable is ranked worse than 95.23% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 68.68
vs XKRX:041830: 16.98
InBody Co's Days Payable
increased
from Jun. 2025 (20.89) to Jun. 2026 (27.32).
It may suggest that InBody Codelayed paying its suppliers.
The historical data trend for InBody Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:041830 vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, InBody Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InBody Co Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InBody Co's Days Payable distribution charts can be found below:
* The bar in red indicates where InBody Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
InBody Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InBody Co (XKRX:041830) has a Days Payable of 27.32 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on InBody Co and its competitors. This is 461% above median its historical median of 4.87. Over the past decade, InBody Co's Days Payable has ranged from 0.88 to 16.98. According to the industry distribution chart, InBody Co ranks #758 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 95.2%.
Is InBody Co's Days Payable too high?
InBody Co's current Days Payable of 27.32 is 461% above median its 10-year median of 4.87. Over the past 10 years, this metric has ranged from a low of 0.88 to a high of 16.98. The Medical Devices & Instruments industry median Days Payable is 68.68. InBody Co's value of 27.32 is 60.2% below this industry median. Based on the distribution chart, InBody Co ranks #758 out of 796 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, InBody Co has a GF Score™ of 86/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InBody Co's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, InBody Co ranks #758 out of 796 companies for Days Payable. This places InBody Co in the lower half of its industry. The industry median Days Payable is 68.68. InBody Co's value of 27.32 is 60.2% below this benchmark. Historically, InBody Co's own Days Payable has ranged from 0.88 to 16.98 over the past decade. While the company's 10-year median is 4.87 vs. the industry median of 68.68, InBody Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.68, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InBody Co's current Days Payable of 27.32 is 60.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on InBody Co and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InBody Co's current Days Payable is 27.32, which is 461% above median its own 10-year median of 4.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InBody Co stock overvalued right now?
Based on GuruFocus' analysis, InBody Co (XKRX:041830) is currently considered Significantly Overvalued. The stock's GF Value™ is ₩35,473.99, compared to a current price of ₩58,900.00 — trading 66% above its estimated fair value. The current Days Payable is 27.32, which is 461% above median its 10-year median of 4.87 and 60.2% below the Medical Devices & Instruments industry median of 68.68. InBody Co's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For InBody Co (XKRX:041830), the current Days Payable is 27.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InBody Co (XKRX:041830) Overvalued in 2026?
Based on GuruFocus' analysis, InBody Co stock appears to be overvalued.
The current stock price of ₩58,900.00 is trading 66% above its estimated GF Value™ of ₩35,473.99.
GuruFocus considers InBody Co to be Significantly Overvalued.
Key valuation signals for XKRX:041830:
Days Payable: 27.32 (461% above median its 10-year median of 4.87)
GF Value™: ₩35,473.99 vs. price of ₩58,900.00 (66% above fair value)
Industry Position: 60.2% below the Medical Devices & Instruments median (#758 of 796)
No single metric tells the full story. See the XKRX:041830 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InBody Co Ltd is a Korea-based company engaged in the manufacturing and distribution of body composition analyzers. The company mainly produces body composition analyzers under the brand name InBody and Lookin'Body. It's InBody series products include InBody720, InBody570, InBody230, InBody J30, and InBody S10.
86GF Score
Get the complete analysis for XKRX:041830
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:041830 has been successfully added to your 
